Galderma Group (GALD) Q4 2024 earnings summary

Executive summary

• Achieved record net sales of $4.4 billion in 2024, up 9.3% year-on-year at constant currency, driven by volume and innovation across all product categories, especially in international markets.

• Core EBITDA surpassed $1 billion for the first time, reaching $1,031 million (+12.9% YoY at constant currency), with a margin of 23.4%, reflecting strong operating leverage and lower-than-expected R&D spend.

• Leverage reduced to 2.3x by year-end, supported by strong cash generation, early debt repayment, and IPO proceeds.

• Major product launches included Nemluvio (biologic for prurigo nodularis and atopic dermatitis) and Relfydess (liquid neuromodulator), both tracking ahead of expectations.

• 2025 guidance targets 10-12% net sales growth at constant currency and ~23% Core EBITDA margin, with margin acceleration expected in the second half as Nemluvio investments ramp up.

Financial highlights

• Net sales reached $4.4 billion, up 9.3% year-on-year at constant currency, with reported growth of 8.0%.

• Core EBITDA grew 12.9% at constant currency, exceeding $1 billion, with margin improving from 23.1% to 23.4%.

• Core net income increased by 138.8% to $496 million (Core EPS $2.09), driven by strong performance, lower financing expenses, and a reduced effective tax rate (25.5%).

• E-commerce sales in dermatological skincare grew over 34% year-on-year, now representing 34% of category sales.

• Cash generation enabled early debt repayment of $256 million; net debt at $2.4 billion.

Outlook and guidance

• 2025 net sales growth expected at 10%-12% at constant currency, with Core EBITDA margin around 23%.

• Largest adverse P&L impact from Nemluvio investments expected in 2025, with margin acceleration in the second half.

• Midterm guidance reconfirmed: low to mid-teens CAGR for net sales and injectable aesthetics, high single-digit to low teens for skincare, and high teens for therapeutic dermatology.

• Nemluvio peak sales expected above $2 billion, breakeven anticipated in 2027.

• Phased net sales growth in 2025, with subdued Q1 due to high prior-year base and temporary market softness.